Tetraphase Pharmaceuticals (NASDAQ:TTPH) will be posting its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Tetraphase Pharmaceuticals to post earnings of ($0.38) per share for the quarter.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%. The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.93 million. On average, analysts expect Tetraphase Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of TTPH remained flat at $$0.33 during midday trading on Tuesday. The stock had a trading volume of 2,242 shares, compared to its average volume of 479,493. Tetraphase Pharmaceuticals has a fifty-two week low of $0.32 and a fifty-two week high of $3.66. The company has a quick ratio of 7.10, a current ratio of 7.28 and a debt-to-equity ratio of 0.53. The business’s 50 day simple moving average is $0.46. The company has a market cap of $18.00 million, a P/E ratio of -0.24 and a beta of 2.28.
A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 6th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 16th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, May 12th. SunTrust Banks dropped their price target on Tetraphase Pharmaceuticals to $4.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, ValuEngine raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. Tetraphase Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $4.20.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Recommended Story: Debt-To-Equity Ratio
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.